• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure.

作者信息

Beusekamp Joost C, Tromp Jasper, Boorsma Eva M, Heerspink Hiddo J L, Damman Kevin, Voors Adriaan A, van der Meer Peter

机构信息

University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

National Heart Centre Singapore & Duke-National University of Singapore, Singapore.

出版信息

Eur J Heart Fail. 2021 Jun;23(6):1049-1052. doi: 10.1002/ejhf.2197. Epub 2021 May 11.

DOI:10.1002/ejhf.2197
PMID:33899306
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8360090/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ad8/8360090/9042174a4fb4/EJHF-23-1049-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ad8/8360090/9042174a4fb4/EJHF-23-1049-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ad8/8360090/9042174a4fb4/EJHF-23-1049-g001.jpg

相似文献

1
Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure.恩格列净抑制钠-葡萄糖协同转运蛋白2对急性心力衰竭患者钾代谢的影响
Eur J Heart Fail. 2021 Jun;23(6):1049-1052. doi: 10.1002/ejhf.2197. Epub 2021 May 11.
2
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?心力衰竭中利尿剂抵抗：恩格列净有作用吗？
Curr Vasc Pharmacol. 2019;17(4):421-424. doi: 10.2174/1570161116666180831124717.
3
Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'.钠-葡萄糖协同转运蛋白2抑制剂：具有多种作用的药物，但哪一种与射血分数保留的心力衰竭相关？关于文章《恩格列净对射血分数保留的心力衰竭的早期获益：EMPEROR-Preserved试验的见解》的信函
Eur J Heart Fail. 2022 Jul;24(7):1323-1324. doi: 10.1002/ejhf.2466. Epub 2022 Mar 9.
4
[Empagliflozin: current indications and aspects for daily clinical practice].恩格列净：日常临床实践的当前适应症及相关方面
G Ital Cardiol (Rome). 2023 Dec;24(12 Suppl 3):3S-12S. doi: 10.1714/4181.41696.
5
FDA Expands Empagliflozin Heart Failure Indication.美国食品药品监督管理局扩大恩格列净治疗心力衰竭的适应症。
JAMA. 2022 Apr 5;327(13):1219. doi: 10.1001/jama.2022.3970.
6
Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials.恩格列净在心力衰竭和 2 型糖尿病治疗中的应用：来自几项大型临床试验的证据。
Int J Med Sci. 2022 Jun 21;19(7):1118-1121. doi: 10.7150/ijms.72772. eCollection 2022.
7
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).恩格列净治疗心力衰竭的代谢效应：一项随机、双盲、安慰剂对照试验（Empire HF Metabolic）
Circulation. 2021 Jun;143(22):2208-2210. doi: 10.1161/CIRCULATIONAHA.120.053463. Epub 2021 Jun 1.
8
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.恩格列净作为附加疗法对因急性失代偿性心力衰竭住院的糖尿病患者的充血和肾功能的影响：一项前瞻性随机对照研究。
Circ Heart Fail. 2021 Mar;14(3):e007048. doi: 10.1161/CIRCHEARTFAILURE.120.007048. Epub 2021 Mar 5.
9
Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.两个故事：一个篇章：EMPEROR-Reduced研究与DAPA-HF研究
Circulation. 2020 Dec 8;142(23):2201-2204. doi: 10.1161/CIRCULATIONAHA.120.051122. Epub 2020 Sep 24.
10
Empagliflozin (Jardiance) for heart failure.恩格列净（欧唐静）用于治疗心力衰竭。
Med Lett Drugs Ther. 2020 Nov 16;62(1611):177-178.

引用本文的文献

1
The impact of sodium-glucose co-transporter-2 inhibitors on serum sodium and potassium in patients with Heart Failure: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂对心力衰竭患者血清钠和钾的影响：一项系统评价和荟萃分析。
BMC Cardiovasc Disord. 2025 Apr 3;25(1):252. doi: 10.1186/s12872-025-04704-w.
2
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.短期使用达格列净导致的急性肾损伤和电解质失衡
Pharmaceuticals (Basel). 2024 Mar 26;17(4):420. doi: 10.3390/ph17040420.

本文引用的文献

1
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.盐皮质激素受体拮抗剂与恩格列净在心力衰竭中的相互作用：EMPEROR-Reduced研究
J Am Coll Cardiol. 2021 Mar 23;77(11):1397-1407. doi: 10.1016/j.jacc.2021.01.044.
2
Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial.钠-葡萄糖协同转运蛋白 2 抑制剂在急性失代偿性心力衰竭住院患者中的应用：EMPULSE 试验的原理和设计。
Eur J Heart Fail. 2021 May;23(5):826-834. doi: 10.1002/ejhf.2137. Epub 2021 Mar 10.
3
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
恩格列净对急性心力衰竭患者肾脏钠和葡萄糖处理的影响。
Eur J Heart Fail. 2021 Jan;23(1):68-78. doi: 10.1002/ejhf.2066. Epub 2020 Dec 16.
4
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
5
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).恩格列净对急性失代偿性心力衰竭（EMPA-RESPONSE-AHF）患者临床结局影响的随机、双盲、安慰剂对照、多中心先导研究。
Eur J Heart Fail. 2020 Apr;22(4):713-722. doi: 10.1002/ejhf.1713. Epub 2020 Jan 7.
6
Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.急性心力衰竭住院期间高钾血症与肾素-血管紧张素-醛固酮系统抑制剂治疗及其与死亡率的关系。
JACC Heart Fail. 2019 Nov;7(11):970-979. doi: 10.1016/j.jchf.2019.07.010. Epub 2019 Oct 9.
7
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
8
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
9
Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.心力衰竭射血分数降低患者中钾离子与肾素-血管紧张素-醛固酮系统抑制剂的应用：BIOSTAT-CHF 研究数据。
Eur J Heart Fail. 2018 May;20(5):923-930. doi: 10.1002/ejhf.1079. Epub 2018 Jan 12.
10
Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality.心力衰竭中长期钾监测与动力学和死亡率的关系。
Circulation. 2018 Mar 27;137(13):1320-1330. doi: 10.1161/CIRCULATIONAHA.117.030576. Epub 2017 Oct 12.